Pharma Equity Group announces successful completion of directed issue of new shares
11 October 2024 - 5:37PM
UK Regulatory
Pharma Equity Group announces successful completion of directed
issue of new shares
|
|
|
|
|
Pharma Equity Group announces successful completion of
directed issue of new shares
11 October 2024
Company Announcement no 26 |
|
With reference to company announcement no. 25 from 4. October 2024,
Pharma Equity Group A/S (the "Company") can hereby announce that
the capital increase of a total nominal value DKK 20,459,277.6
corresponding to 204,592,776 new shares each with a nominal value
of DKK 0.1 at a price of DKK 0.25 per share has been completed and
the capital increase has been registered with the Danish Business
Authority.
In accordance with section 32 of the Danish Capital Markets Act,
the Company announces that after registration of the share capital
increase, the Company's share capital amounts to nominally DKK
122,755,665.9 divided into shares of DKK 0.1 each. The total number
of voting rights in the Company are 1,227,556,659.
The new shares are expected to be admitted to trading on Nasdaq
Copenhagen on 16 October 2024 under the ISIN code of the
Company's existing shares (DK0061155009).
The issuance of the new shares will be reflected in the Company's
articles of association, which can be found on the Company's
website.
For further information, please contact:
|
|
Thomas Kaas
Selsø, CEO of Pharma Equity Group A/S, phone: +45 4022 2114
Christian Vinding Thomsen, Chairman of the Board of Directors of
Pharma Equity Group A/S, phone: +45 2622 7222 |
|
About Pharma Equity Group A/S
Pharma Equity Group, a listed company on the Nasdaq Copenhagen
stock exchange, is fully dedicated to advancing the medical
projects of its subsidiary, Reponex Pharmaceuticals A/S. With an
unwavering focus on healthcare, Pharma Equity Group's primary
objective is to bring significant value to Reponex Pharmaceuticals'
medical projects.
The company is committed to providing extensive support,
resources, and expertise to drive the development and success of
these projects. As a strategic partner, Pharma Equity Group works
closely with Reponex Pharmaceuticals, prioritizing the advancement
of innovative medical solutions and breakthrough therapies. Every
effort is currently directed towards ensuring the utmost success
and impact of Reponex Pharmaceuticals' medical projects, with an
unwavering dedication to improving global healthcare outcomes. Only
when the full potential of Reponex Pharmaceuticals has been
unfolded is the intention to explore opportunities to invest in
other companies. This approach ensures a strong commitment to the
current medical projects and their development, while – on the
longer term – remaining open to new strategic investments for
continuous growth. |
- Company Announcement nr 26 Cap Completion_UK_111024
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Dec 2024 to Jan 2025
Pharma Equity Group A/s (LSE:0REU)
Historical Stock Chart
From Jan 2024 to Jan 2025